Gilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street Forecasts

{
  "signal_id": "3e2f7631-1c51-885a-8acd-562866f18880",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-08-04T22:26:47+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/le-chiffre-d-affaires-de-gilead-au-deuxieme-trimestre-progresse-de-8-depassant-les-previsions-de-wall-street-35787b6791fa0cf2ccc2f76df9902fd7",
    "title": "Gilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street Forecasts - Boursorama",
    "excerpt": "((Automated translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto))\n* Company posts adjusted loss of $6.75 per share, citing acquisition costs\n* Revenue rises 10% to $7.8 billion, exceeding forecasts\n* Yeztugo sales total $232 million for the quarter\n(Adds details from conference call in paragraphs 4 and 9) by Deena Beasley and Puyaan Singh\nGilead Sciences GILD.O announced on Tuesday that its second-quarter product sales rose 8%, driven by double-digit increases in its HIV drugs, but the company posted a quarterly loss due to costs related to a series of acquisitions.\nThe company's overall revenue increased 10% to $7.8 billion, exceeding Wall Street forecasts of $7.4 billion, according to LSEG data.\nGilead attributed these results to strong sales of its HIV products, the cancer drug Trodelvy, and the liver disease drug Livdelzi.\n\"HIV product sales grew 12%, reflecting continued strength in the treatment market and the rapid expansion of our pre-exposure prophylaxis (PrEP) business, which confirms our forecasts for core business revenue growth for 2026,\" said Daniel O'Day, Gilead's CEO, in a statement.\nGilead also expects 9% to 10% growth in its annual HIV product sales, compared to a previously forecast 8% increase.\nHowever, Johanna Mercier, Chief Commercial and General Affairs Officer, indicated that...",
    "summary": "Gilead Sciences reported an adjusted loss per share of $6.75 for the second quarter, better than the analyst consensus expectation of a $7.24 loss.",
    "planning": false,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-3.jpg",
    "confidence": 0.95,
    "published_at": "2026-08-04T22:26:47Z",
    "article_sentence": "In the second quarter, Gilead reported an adjusted loss per share of $6.75, while Wall Street analysts on average expected a loss of $7.24.",
    "amount_normalized": 6
  }
}

curl https://signals.autobound.ai/v1/signals/3e2f7631-1c51-885a-8acd-562866f18880 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'